Recent Updates
Recently added Catalysts
SLN Positive Sentiment Score: 70/100

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in P

Key Takeaway: Silence Therapeutics has announced its financial results for the second quarter of 2025, highlighting encouraging updates on its SANRECO Phase 1 trial data for divesiran, which is being developed as a first-in-class siRNA therapy for polycythemia vera. The company is on track for full enrollment of the Phase 2 study by the end of the year and retains a cash runway that extends into 2028. However, Silence continues to face challenges with rising net losses and overall financial performance concerns.

Market Sentiment Analysis

POSITIVE FACTORS

  • Promising updated SANRECO Phase 1 data supporting divesiran's potential.
  • Phase 2 study on track for full enrollment by year-end 2025.
  • Healthy cash reserves of approximately $114.2 million to support operations.
  • Company prioritizing investments in high potential areas.

CONCERNS & RISKS

  • Reported net losses have increased year-over-year.
  • Dependence on successful completion of the SANRECO Phase 2 trial enrollment.
  • Financial performance shows significant losses particularly in revenue.

Full Press Release Details

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for
Divesiran as First-in-Class siRNA in PV
SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025
LONDON, Silence Therapeutics plc, Nasdaq: SLN ( Silence or the Company ), a global clinical-stage company developing novel siRNA (short
interfering RNA) therapies, today reported its financial results for the second quarter ended June 30, 2025, and reviewed recent business highlights.
The updated data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of divesiran as a first-in-class siRNA in PV, said Craig Tooman, President and Chief Executive Officer at Silence. The SANRECO Phase 2 trial of divesiran in PV patients continues to
progress towards full enrollment this year and remains our top priority.
Rhonda Hellums, Silence s Chief Financial Officer, said, We are
continuing to prioritize investments in key areas where we see the highest potential to deliver near term value, including ensuring the successful completion of the SANRECO Phase 2 trial enrollment by
year-end. We ended the quarter with approximately $114.2 million in cash and cash equivalents and short-term investments and are reiterating our cash runway guidance into 2028.
Second Quarter 2025 & Recent Business Highlights
Divesiran for Polycythemia Vera (PV)
Zerlasiran for Cardiovascular Disease
Second Quarter 2025 Financial Highlights
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people s lives by silencing diseases through precision
engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD platform to create innovative siRNAs designed to precisely target and
silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information,
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as aim, anticipate, assume, believe, contemplate,
continue, could, design, due, estimate, expect, goal, intend, may, objective, plan, positioned,
potential, predict, seek, should, target, will, would and other similar expressions that are predictions of or indicate future events and future trends, or the
negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to,
statements about: the Company s business strategy and plans, including the Company s clinical development activities and timelines; the therapeutic benefits of the Company s product candidates; the timing of patient enrollment of the
SANRECO Phase 2 trial; the progression and advancement of collaborations; the Company s ability to deliver near term value; and the Company s anticipated extended cash runway. Forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company s history of net
operating losses; the company s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company s product candidates; the company s ability to obtain regulatory approval of
and successfully commercialize its product candidates; any undesirable side effects or other properties of the company s product candidates; the company s reliance on third-party suppliers and manufacturers; the outcomes of any future
collaboration agreements; and the company s ability to adequately maintain intellectual property rights for its product
candidates. These and other risks are described in greater detail under the section titled Risk Factors contained in the company s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made
pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise.
Silence Therapeutics plc
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except share and per share data)
June 30, 2025 December 31, 2024
Current assets
Cash and cash equivalents $ 41,739 $ 121,330
Short-term investments 72,416 26,004
R&D benefit receivable 19,957 24,396
Other current assets 14,356 14,664
Trade receivables 85 972
Total current assets 148,553 187,366
Property, plant and equipment 1,775 1,818
Operating lease right-of-use assets 58 157
Goodwill 10,617 9,392
Other intangible assets 317 312
Other long-term assets 3,913 3,590
Total assets $ 165,233 $ 202,635
Current liabilities
Contract liabilities $ (457 ) $ (306 )
Trade and other payables (14,311 ) (16,399 )
Operating lease liabilities, current (117 )
Total current liabilities (14,768 ) (16,822 )
Contract liabilities (56,310 ) (51,790 )
Total liabilities $ (71,078 ) $ (68,612 )
Commitments and contingencies (Note 11)
Shareholders equity
Ordinary shares - par value 0.05 per share; 141,701,848 shares issued at June 30, 2025 (December 31, 2024: 141,674,074) (10,290 ) (10,288 )
Additional paid-in capital (615,113 ) (609,560 )
Accumulated deficit 529,844 474,044
Accumulated other comprehensive loss 1,404 11,781
Total shareholders equity (94,155 ) (134,023 )
Total liabilities and shareholders equity $ (165,233 ) $ (202,635 )
Silence Therapeutics plc
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited, in thousands, except share and per share data)
Three months ended June 30, Six months ended June 30,
2025 2024 2025 2024
Revenue $ 224 $ 756 $ 366 $ 16,455
Cost of sales (85 ) (3,333 ) (139 ) (6,133 )
Gross profit 139 (2,577 ) 227 10,322
Research and development costs (17,647 ) (13,802 ) (38,460 ) (25,647 )
General and administrative expenses (5,131 ) (7,009 ) (12,815 ) (13,644 )
Restructuring charges (1,324 ) (1,324 )
Operating loss (23,963 ) (23,388 ) (52,372 ) (28,969 )
Foreign currency (loss)/gain, net (6,613 ) (222 ) (10,382 ) 129
Other income, net 861 1,351 1,830 2,017
Benefit from R&D credit 2,371 2,732 5,050 5,228
Loss before income tax expense (27,344 ) (19,527 ) (55,874 ) (21,595 )
Income tax expense (10 ) (228 ) (10 ) (472 )
Net Loss $ (27,354 ) $ (19,755 ) $ (55,884 ) $ (22,067 )
Loss per share (basic and diluted) $ (0.19 ) $ (0.14 ) $ (0.39 ) $ (0.16 )
Weighted average shares outstanding (basic and diluted) 141,696,047 140,208,929 141,687,438 136,045,022

Frequently Asked Questions

What recent data did Silence Therapeutics present?

Silence Therapeutics presented updated SANRECO Phase 1 data at EHA 2025.

What is the focus of the SANRECO Phase 2 trial?

The SANRECO Phase 2 trial focuses on divesiran for patients with Polycythemia Vera.

What were Silence Therapeutics' cash reserves as of Q2 2025?

Silence ended Q2 2025 with approximately $114.2 million in cash and equivalents.

What potential does divesiran have according to Silence's CEO?

Divesiran shows promising potential as a first-in-class siRNA in Polycythemia Vera.

What areas does Silence Therapeutics target with its therapies?

Silence targets cardiovascular disease, hematology, and rare diseases with its therapies.

Last updated: Aug 7, 2025